{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T12:59:22Z","timestamp":1783688362391,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005205","name":"J&J Innovative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["HHSN261201800032I"],"award-info":[{"award-number":["HHSN261201800032I"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["1NU58DP007156"],"award-info":[{"award-number":["1NU58DP007156"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014479","name":"Georgia Department of Public Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019886","name":"Legend Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019886","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006034","name":"University of Southern California","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006034","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005565","name":"Johnson & Johnson Innovative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.clml.2025.01.009","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T19:23:37Z","timestamp":1737660217000},"page":"e394-e403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Real-World Treatment Patterns and Outcomes in Patients With Lenalidomide-Refractory Multiple Myeloma With 1 to 3 Prior Lines: SEER-Medicare Database"],"prefix":"10.1016","volume":"25","author":[{"given":"Binod","family":"Dhakal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghua","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"Schecter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1414-2387","authenticated-orcid":false,"given":"William","family":"Deraedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Slaughter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5015-3713","authenticated-orcid":false,"given":"Jianming","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seina","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Cost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mythili","family":"Koneru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2025.01.009_bib0001","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010155","article-title":"How to manage patients with lenalidomide-refractory multiple myeloma","volume":"15","author":"de Arriba de la Fuente","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2025.01.009_bib0002","unstructured":"The National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in oncology: multiple myeloma (Version 2.2023). Accessed February 1, 2023. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1445."},{"issue":"2","key":"10.1016\/j.clml.2025.01.009_bib0003","first-page":"e528","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"Hemasphere"},{"issue":"2","key":"10.1016\/j.clml.2025.01.009_bib0004","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.3390\/curroncol30020179","article-title":"Relapsed\/refractory multiple myeloma: a review of available therapies and clinical scenarios encountered in myeloma relapse","volume":"30","author":"Bhatt","year":"2023","journal-title":"Curr Oncol"},{"issue":"10","key":"10.1016\/j.clml.2025.01.009_bib0005","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1182\/bloodadvances.2020001508","article-title":"Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma","volume":"4","author":"Alonso","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.clml.2025.01.009_bib0006","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jgo.2017.09.007","article-title":"The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed\/refractory multiple myeloma in the era of novel therapies","volume":"9","author":"Hari","year":"2018","journal-title":"J Geriatr Oncol"},{"issue":"4","key":"10.1016\/j.clml.2025.01.009_bib0007","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/jha2.743","article-title":"Difficult-to-treat patients with relapsed\/refractory multiple myeloma: a review of clinical trial results","volume":"4","author":"Raab","year":"2023","journal-title":"EJHaem"},{"key":"10.1016\/j.clml.2025.01.009_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.844779","article-title":"Beyond clinical trials in patients with multiple myeloma: a critical review of real-world results","volume":"12","author":"Bertamini","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2025.01.009_bib0009","unstructured":"SEER-Medicare Linked Data Resource. Accessed June 16, 2024. https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/overview\/."},{"key":"10.1016\/j.clml.2025.01.009_bib0010","unstructured":"Institute NC. SEER-Medicare: how the SEER & Medicare data are linked; 2020. Accessed June 20, 2024. https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/overview\/linked.html."},{"issue":"11","key":"10.1016\/j.clml.2025.01.009_bib0011","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1634\/theoncologist.2016-0104","article-title":"Analysis of real-world data on overall survival in multiple myeloma patients with \u22653 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD","volume":"21","author":"Usmani","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2025.01.009_bib0012","unstructured":"National Cancer Institute. NCI Comorbidity Index overview; 2023. Accessed April 15, 2024. https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/considerations\/comorbidity.html."},{"issue":"11","key":"10.1016\/j.clml.2025.01.009_bib0013","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1634\/theoncologist.2017-0229","article-title":"FDA approval summary: daratumumab for treatment of multiple myeloma after one prior therapy","volume":"22","author":"Bhatnagar","year":"2017","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.clml.2025.01.009_bib0014","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.clml.2025.01.009_bib0015","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/bloodadvances.2023010026","article-title":"Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study","volume":"7","author":"Usmani","year":"2023","journal-title":"Blood Adv"},{"issue":"10292","key":"10.1016\/j.clml.2025.01.009_bib0016","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2025.01.009_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106576","article-title":"Isatuximab plus pomalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis","volume":"104","author":"Bringhen","year":"2021","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.clml.2025.01.009_bib0018","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1200\/JCO.21.02815","article-title":"Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.01.009_bib0019","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/14656566.2017.1418856","article-title":"Triplet vs. doublet drug regimens for managing multiple myeloma","volume":"19","author":"Offidani","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clml.2025.01.009_bib0020","article-title":"Daratumumab for the management of newly diagnosed and relapsed\/refractory multiple myeloma: current and emerging treatments","volume":"10","author":"Offidani","year":"2020","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.01.009_bib0021","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.clml.2017.12.012","article-title":"Prolonged duration of therapy is associated with improved survival in patients treated for relapsed\/refractory multiple myeloma in routine clinical care in the United States","volume":"18","author":"Hari","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.clml.2025.01.009_bib0022","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/ejh.14193","article-title":"Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab-na\u00efve relapsed multiple myeloma","volume":"112","author":"Dima","year":"2024","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2025.01.009_bib0023","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00277-023-05443-8","article-title":"A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed\/refractory multiple myeloma patients: a report from the triveneto myeloma working group","volume":"103","author":"Baril\u00e0","year":"2024","journal-title":"Ann Hematol"},{"issue":"19","key":"10.1016\/j.clml.2025.01.009_bib0024","doi-asserted-by":"crossref","first-page":"5062","DOI":"10.1182\/bloodadvances.2024012640","article-title":"Real-world treatment patterns and outcomes in relapsed\/refractory multiple myeloma (1-3 prior lines): flatiron database","volume":"8","author":"Dhakal","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.01.009_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115157","article-title":"Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: analysis of individual patient-level data from daratumumab clinical trials","volume":"215","author":"Yong","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2025.01.009_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.703233","article-title":"Defining unmet need following lenalidomide refractoriness: real-world evidence of outcomes in patients with multiple myeloma","volume":"11","author":"Lecat","year":"2021","journal-title":"Front Oncol"},{"issue":"55","key":"10.1016\/j.clml.2025.01.009_bib0027","first-page":"3","article-title":"Updated overview of the SEER-Medicare data: enhanced content and applications","volume":"2020","author":"Enewold","year":"2020","journal-title":"J Natl Cancer Inst Monogr"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:17:28Z","timestamp":1762600648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025000229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2152265025000229"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.01.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Treatment Patterns and Outcomes in Patients With Lenalidomide-Refractory Multiple Myeloma With 1 to 3 Prior Lines: SEER-Medicare Database","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}